Timothy Paul Copeland

Dr. Timothy Paul Copeland

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2023 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
EKElaine Ku
Elaine Ku
TCTimothy Paul Copeland
Timothy Paul Copeland
CMCharles E. McCulloch
Charles E. McCulloch
CFChristopher Freise
Christopher Freise
SLSabrina Legaspi
Sabrina Legaspi
KJKirsten L. Johansen
Kirsten L. Johansen
Significance Statement: The Advancing American Kidney Health Initiative aims to increase rates of utilization of peritoneal dialysis (PD) in the United States. One of the first steps to PD is successful catheter placement, which can be performed by surgeons, interventional radiologists, or nephrologists. We examined the association between operator subspecialty and risk of needing a follow-up procedure in the first 90 days after initial PD catheter implantation. Overall, we found that 15.5% of catheters required revision, removal, or a second catheter placement within 90 days. The odds of requiring a follow-up procedure was 36% higher for interventional radiologists and 86% higher for interventional nephrologists compared with general surgeons. Further research is needed to understand how to optimize the function of catheters across different operator types. Background: The US government has implemented incentives to increase the use of PD. Successful placement of PD catheters is an important step to increasing PD utilization rates. Our objective was to compare initial outcomes after PD catheter placement by different types of operators. Methods: We included PD-naïve patients insured by Medicare who had a PD catheter inserted between 2010 and 2019. We examined the association between specialty of the operator (general surgeon, vascular surgeon, interventional radiologist, or interventional nephrologist) and odds of needing a follow-up procedure, which we defined as catheter removal, replacement, or revision within 90 days of the initial procedure. Mixed logistic regression models clustered by operator were used to examine the association between operator type and outcomes. Results: We included 46,973 patients treated by 5205 operators (71.1% general surgeons, 17.2% vascular surgeons, 9.7% interventional radiologists, 2.0% interventional nephrologists). 15.5% of patients required a follow-up procedure within 90 days of the initial insertion, of whom 2.9% had a second PD catheter implanted, 6.6% underwent PD catheter removal, and 5.9% had a PD catheter revision within 90 days of the initial insertion. In models adjusted for patient and operator characteristics, the odds of requiring a follow-up procedure within 90 days were highest for interventional nephrologists (HR, 1.86; 95% confidence interval [CI], 1.56 to 2.22) and interventional radiologists (odds ratio, 1.36; 95% CI, 1.17 to 1.58) followed by vascular surgeons (odds ratio, 1.06; 95% CI, 0.97 to 1.14) compared with general surgeons. Conclusions: The probability of needing a follow-up procedure after initial PD catheter placement varied by operator specialty and was higher for interventionalists and lowest for general surgeons.

19 February 2025 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
KJKristen Jablonski
Kristen Jablonski
TCTimothy Paul Copeland
Timothy Paul Copeland
EKElaine Ku
Elaine Ku
MSMark J. Sarnak
Mark J. Sarnak
BGBerenice Gitomer
Berenice Gitomer
MCMichel Chonchol
Michel Chonchol
Key Points: Higher body mass index increased risk of progression to ESKD in patients with early-stage autosomal dominant polycystic kidney disease. Higher body mass index did not increase the risk of progression to ESKD in patients with late-stage autosomal dominant polycystic kidney disease. Background: Prior research has linked higher body mass index (BMI) and greater visceral adiposity with more rapid progression of early-stage autosomal dominant polycystic kidney disease (ADPKD). We now evaluate the association between overweight and obesity in patients with early- and late-stage ADPKD with progression to ESKD. Methods: Participants with early-stage ADPKD (study A; N=556; eGFR: 91±17 ml/min per 1.73 m2) and late-stage ADPKD (study B; N=483; eGFR: 48±12 ml/min per 1.73 m2) who participated in the Halt Progression of Polycystic Kidney Disease (HALT) polycystic kidney disease trials were categorized by BMI as normal weight (18.5–24.9 kg/m2; ref; n=357), overweight (25.0–29.9 kg/m2; n=384), or obese (≥30 kg/m2; n=298). Kaplan–Meier survival analysis and multivariate Cox proportional hazard models were used to determine the association of baseline BMI as a continuous and categorical variable with risk of ESKD (according to the United States Renal Data System) over a median (interquartile range) follow-up period of 12.2 (7.5–13.3; study A) and 7.3 (5.1–11.7; study B) years (primary outcome). All-cause mortality (National Death Index) was also considered as a competing risk (Fine and Gray method). Results: The number of ESKD events was greater with overweight (n=24) and obesity (n=23) in HALT study A versus normal weight (n=12) but not in HALT study B (normal weight: n=89, overweight: n=102, obese: n=92). In fully adjusted models, higher BMI was associated with risk of progression to ESKD in study A (hazard ratio [HR (95% confidence interval)], 1.09 [1.03 to 1.15] per unit higher BMI) but not in study B (HR, 0.98 [0.96 to 1.00]). Obesity was associated with increased risk of ESKD (HR, 2.71 [1.22 to 6.02] versus normal weight) in study A only. Results were similar when considering death as a competing risk. Conclusions: Higher BMI, particularly obesity, increased the risk of progression to ESKD in patients with early-stage ADPKD but not in those with late-stage ADPKD.

1 October 2019 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
TCTimothy Paul Copeland
Timothy Paul Copeland
PLPeter Lawrence
Peter Lawrence
KWKaren Woo
Karen Woo

1 January 2020 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
TCTimothy Paul Copeland
Timothy Paul Copeland
RHRobert J. Hye
Robert J. Hye
PLPeter F. Lawrence
Peter F. Lawrence
KWKaren Woo
Karen Woo

9 June 2023 in Pediatric Diabetes
Verified
Journal Article
Open access
PDF file
EEEstelle M. Everett
Estelle M. Everett
TCTimothy Paul Copeland
Timothy Paul Copeland
LWLauren E. Wisk
Lauren E. Wisk
LCLily C. Chao
Lily C. Chao
Background. There is a paucity of data on the risk factors for the hyperosmolar hyperglycemic state (HHS) compared with diabetic ketoacidosis (DKA) in pediatric type 2 diabetes (T2D). Methods. We used the national Kids Inpatient Database to identify pediatric admissions for DKA and HHS among those with T2D in the years 2006, 2009, 2012, and 2019. Admissions were identified using ICD codes. Those aged <9yo were excluded. We used descriptive statistics to summarize baseline characteristics and Chi-squared test and logistic regression to evaluate factors associated with admission for HHS compared with DKA in unadjusted and adjusted models. Results. We found 8,961 admissions for hyperglycemic emergencies in youth with T2D, of which 6 were due to HHS and 94 were for DKA. These admissions occurred mostly in youth 1720years old (64) who were non-White (Black 31, Hispanic 20), with public insurance (49) and from the lowest income quartile (42). In adjusted models, there were increased odds for HHS compared to DKA in males (OR 1.77, 95 CI 1.422.21) and those of Black race compared to those of White race (OR 1.81, 95 CI 1.342.44). Admissions for HHS had 11.3-fold higher odds for major or extreme severity of illness and 5.0-fold higher odds for mortality. Conclusion. While DKA represents the most admissions for hyperglycemic emergencies among pediatric T2D, those admitted for HHS had higher severity of illness and mortality. Male gender and Black race were associated with HHS admission compared to DKA. Additional studies are needed to understand the drivers of these risk factors.

13 July 2018 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
BFBenjamin L. Franc
Benjamin L. Franc
TCTimothy Paul Copeland
Timothy Paul Copeland
RTRobert Thombley
Robert Thombley
MPMiran Park
Miran Park
BMBen Marafino
Ben Marafino
RDR. Adams Dudley
R. Adams Dudley
Background: The objective of this study was to examine the presence and magnitude of US geographic variation in use rates of both recommended and high-cost imaging in young patients with early-stage breast cancer during the 18 month period after surgical treatment of their primary tumor. Methods: Using the Truven Health MarketScan Commercial Database, a descriptive analysis was conducted of geographic variation in annual rates of dedicated breast imaging and high-cost body imaging of 36,045 women aged 18 to 64 years treated with surgery for invasive unilateral breast cancer between 2010 and 2012. Multivariate hierarchical analysis examined the relationship between likelihood of imaging and patient characteristics, with metropolitan statistical area (MSA) serving as a random effect. Patient characteristics included age group, BRCA1/2 carrier status, family history of breast cancer, combination of breast surgery type and radiation therapy, drug therapy, and payer type. All MSAs in the United States were included, with areas outside MSAs within a given state aggregated into a single area for analytic purposes. Results: Descriptive analysis of rates of imaging use and intensity within MSA regions revealed wide geographic variation, irrespective of treatment cohort or age group. Increased probability of recommended postoperative dedicated breast imaging was primarily associated with age and treatment including both surgery and radiation therapy, followed by MSA region (odds ratio, 1.42). Increased probability of PET use—a high-cost imaging modality for which postoperative routine use is not recommended in the absence of specific clinical findings—was primarily associated with surgery type followed by MSA region (odds ratio, 1.82). Conclusions: In patients with breast cancer treated for low-risk disease, geography has effects on the rates of posttreatment imaging, suggesting that some patients are not receiving beneficial dedicated breast imaging, and high-cost nonbreast imaging may not be targeted to those groups most likely to benefit.